CCL20 antibody (FITC)

Catalog No. ABIN192397

Product Details anti-CCL20 Antibody

Target: CCL20 (Chemokine (C-C Motif) Ligand 20 (CCL20))

Reactivity: Human

Host: Mouse

Clonality: Monoclonal

Conjugate: This CCL20 antibody is conjugated to FITC

Application: Flow Cytometry (FACS), Immunohistochemistry (Frozen Sections) (IHC (fro)), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)), Immunoprecipitation (IP)

Specificity: The antibody UCHL1 recognizes CD45R0, a 180 kDa low molecular weight isoform of the leukocyte common antigen (LCA). The antigen is expressed on a subset of memory/activated T cells and on cortical thymocytes.
HLDA III, WS Code NL 826
HLDA III, WS Code T 128
HLDA IV, WS Code NL 31
HLDA V, WS Code BP BP460
HLDA V, WS Code T T-081
HLDA V, WS Code T T-CD45.43

Cross-Reactivity (Details): Human

Immunogen: Human IL-2 dependent T cells

Clone: UCHL1

Isotype: IgG2a

Application Details

Application Notes: The reagent is designed for Flow Cytometry analysis of human blood cells using 20 μ,l reagent / 100 μ,l of whole blood or 106 cells in a suspension.The content of a vial (2 ml) is sufficient for 100 tests.

Comment:

The purified antibody is conjugated with Fluorescein isothiocyanate (FITC) under optimum conditions. The reagent is free of unconjugated FITC and adjusted for direct use. No reconstitution is necessary.

Restrictions: For Research Use only

Handling

Reconstitution: No reconstitution is necessary.

Buffer: The reagent is provided in stabilizing phosphate buffered saline (PBS) solution containing 15 mM sodium azide.

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Handling Advice: Do not freeze.
Avoid prolonged exposure to light.

Storage: 4 °C

Storage Comment: Store in the dark at 2-8°C. Do not freeze. Avoid prolonged exposure to light. Do not use after expiration date stamped on vial label.

References for anti-CCL20 antibody (ABIN192397)

Kalina, Bakardjieva, Blom, Perez-Andres, Barendregt, Kanderová, Bonroy, Philippé, Blanco, Pico-Knijnenburg, Paping, Wolska-Kuśnierz, Pac, Tkazcyk, Haerynck, Akar, Formánková, Freiberger, Svatoň et al.: "EuroFlow Standardized Approach to Diagnostic Immunopheneotyping of Severe PID in Newborns and Young Children. ..." in: Frontiers in immunology, Vol. 11, pp. 371, (2020) (PubMed).

van Dongen, van der Burg, Kalina, Perez-Andres, Mejstrikova, Vlkova, Lopez-Granados, Wentink, Kienzler, Philippé, Sousa, van Zelm, Blanco, Orfao: "EuroFlow-Based Flowcytometric Diagnostic Screening and Classification of Primary Immunodeficiencies of the Lymphoid System." in: Frontiers in immunology, Vol. 10, pp. 1271, (2019) (PubMed).

Akbar, Terry, Timms, Beverley, Janossy: "Loss of CD45R and gain of UCHL1 reactivity is a feature of primed T cells." in: Journal of immunology (Baltimore, Md. : 1950), Vol. 140, Issue 7, pp. 2171-8, (1988) (PubMed).

Beverley, Merkenschlager, Terry: "Phenotypic diversity of the CD45 antigen and its relationship to function." in: Immunology. Supplement, Vol. 1, pp. 3-5, (1988) (PubMed).

Terry, Brown, Beverley: "The monoclonal antibody, UCHL1, recognizes a 180,000 MW component of the human leucocyte-common antigen, CD45." in: Immunology, Vol. 64, Issue 2, pp. 331-6, (1988) (PubMed).

Beverley: "Human T cell subsets." in: Immunology letters, Vol. 14, Issue 4, pp. 263-7, (1987) (PubMed).

Norton, Ramsay, Smith, Beverley, Isaacson: "Monoclonal antibody (UCHL1) that recognises normal and neoplastic T cells in routinely fixed tissues." in: Journal of clinical pathology, Vol. 39, Issue 4, pp. 399-405, (1986) (PubMed).

Smith, Brown, Rowe, Callard, Beverley: "Functional subsets of human helper-inducer cells defined by a new monoclonal antibody, UCHL1." in: Immunology, Vol. 58, Issue 1, pp. 63-70, (1986) (PubMed).

Target Details for CCL20

Target: CCL20 (Chemokine (C-C Motif) Ligand 20 (CCL20))

Alternative Name: CD45R0 (CCL20 Products)

Synonyms: MIP-3ALPHA antibody, CCL20 antibody, si:dkey-150o13.1 antibody, CKb4 antibody, LARC antibody, MIP-3-alpha antibody, MIP-3a antibody, MIP3A antibody, SCYA20 antibody, ST38 antibody, MIP-3A antibody, MIP-3[a] antibody, Scya20 antibody, exodus-1 antibody, C-C motif chemokine ligand 20 antibody, chemokine (C-C motif) ligand 20b antibody, chemokine (C-C motif) ligand 20 antibody, CCL20 antibody, ccl20b antibody, Ccl20 antibody

Background: CD45R0 is the shortest isoform of a receptor-type protein tyrosine phosphatase, CD45 glycoprotein. CD45 is crucial in lymphocyte development and antigen signaling, serving as an important regulator of Src-family kinases, promotes cell survival by modulating integrin-mediated signal transduction pathway and is also involved in DNA fragmentation during apoptosis. CD45 isoforms differ in their extracellular domains, whereas they share identical transmembrane and cytoplasmic domains. These isoforms differ in their ability to translocate into the glycosphingolipid-enriched membrane domains and their expression depends on cell type and physiological state of the cell. CD45R0 is expressed e.g. on macrophages, CD8+ T cells, activated T cells and myeloma cells.

Pathways: The Global Phosphorylation Landscape of SARS-CoV-2 Infection